Premium

Pfizer approval may help erase doubts among vaxx-hesitant

Published by
By Editorial staff

Hopefully, the news that the US Food and Drug Administration (FDA) has given full approval to the two-dose Pfizer Covid vaccine will help erase some of the doubts among the vaxx-hesitant.

This approval means as much as any other FDA approval for other drugs out there … and which some of the vaxx hesitant take without a moment’s thought.

However, given the heat which has been generated around the issue of vaccines and the misleading information by the anti-vaxx lobby we worry that this will still not be enough to convince the doubters.

Advertisement

All manner of reasons ranging from the extremist conspiracy theories that this is all part of a plot to control the world; to the freedom lobby which claims people are being coerced into getting jabbed against their will will be offered as part of the rearguard action.

The FDA approval cements the fact that the vaccines (and there will be other approvals in time) are safe and that the fear that they were developed in a rush is unfounded.

The evidence from the US and the UK, and other countries, is that the vaccinated are far less likely to experience severe cases of Covid and, therefore, take up precious hospital beds.

Advertisement

Those are facts beyond question – and we should not entertain a debate on them, no matter the cries of “censorship” which will result.

But perhaps the only way to change anti-vaxx minds is through their pockets. The medical sector is run as a business and they are going to start assessing the risks posed to that business by those who pose a higher risk through their reckless behaviour.

It won’t be long before anti-vaxxers are charged higher medical aid and life insurance premiums. Which iscorrect.

Advertisement

Why should those of us who do the right thing pay for the anti-social behaviour of those who don’t?

For more news your way

Download our app and read this and other great stories on the move. Available for Android and iOS.

Published by
By Editorial staff
Read more on these topics: COVID-19 vaccineEditorialsPfizer